Astec LifeSciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
For the full year, sales was INR 4,581.81 million compared to INR 6,281.66 million a year ago. Revenue was INR 4,638.25 million compared to INR 6,412.26 million a year ago. Net loss was INR 469.3 million compared to net income of INR 255.65 million a year ago. Basic loss per share from continuing operations was INR 23.96 compared to basic earnings per share from continuing operations of INR 13.02 a year ago. Diluted loss per share from continuing operations was INR 23.96 compared to diluted earnings per share from continuing operations of INR 13.02 a year ago.